Table 5.
Survival after an allotransplant for CML in 1st chronic phase.
| Interval | N | Median age (y) | Conditioning | Donor | 1-y | 2-y | 3-y | 5-y | 10-y | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Millot et al. [97] | SGFMTC | 1982–1998 | 42 | 14 | MA | REL | 87% | 85% | 77% | 73% | 73% |
| Cwynarski et al. [98] | EBMT | 1985–2001 | 156 | 14 | NR | REL | 78% | 75% | 75% | 72% | 70% |
| Arora et al. [99] | CIBMTR | 1988–2003 | 3514 | 36 | MA | REL | 74% | 65% | 63% | 63% | 60% |
| Arora et al. [99] | CIBMTR | 1988–2003 | 531 | 37 | MA | UNR | 70% | 63% | 58% | 55% | 50% |
| Radich et al. [100] | Seattlea | 1995–2000 | 131 | 43 | MA | REL | 91% | 86% | 86% | NA | NA |
| Gratwohl et al. [61] | German Study IIIa | 1997–2004 | 151 | 38 | MA | REL | 90% | 85% | 82% | 78% | 76% |
| Gratwohl et al. [61] | German Study III | 1997–2004 | 148 | 41 | MA | UNR | 97% | 85% | 77% | 76% | 76% |
| Bacher et al. [62] | German Registry | 1998–2004 | 1084 | 40 | MA 62% | REL 61% | 67% | 65% | 65% | 64% | 64% |
| Ohashi et al. [101] | Japanese Registry | 2000–2009 | 531 | 40 | MA 89% | UNR 51% | 87% | 86% | 85% | 85% | 78% |
| Chaudury et al. [102] | CIBMTR | 2001–2010 | 224 | 24 | MA | REL | 90% | 88% | 85% | 83% | NA |
| Chaudury et al. [102] | CIBMTR | 2001–2010 | 225 | 24 | MA | UNR | 80% | 76% | 72% | 68% | NA |
| Lee et al. [103] | Koreana | 2001–2012 | 47 | 32 | MA 77% | UNR 43% | 88% | 86% | 86% | NA | NA |
| Lee et al. [103] | Korean | 2001–2012 | 50 | 33 | MA 48% | UNR 42% | 90% | 86% | 80% | NA | NA |
| Koenecke et al. [104] | EBMT | 2002–2005 | 193 | 31 | MA | REL | 90% | 87% | 86% | 85% | 84% |
| Saussele et al. [105] | German Study IVa | 2003–2008 | 19 | 35 | MA 79% | REL 53% | 95% | 88% | 88% | NA | NA |
| Saussele et al. [105] | German Study IV | 2003–2008 | 37 | 38 | MA 65% | UNR 70% | 95% | 95% | 94% | NA | NA |
aData are estimated from graphs (±1%). SGFMTC Société Française de Greffe de Moelle et de Thérapie Cellulaire, EBMT European Group for Marrow and Blood Transplantation, CIBMTR Center for International Blood and Marrow Transplantation, MA myelo-ablative, REL related donor, UNR unrelated donor, NR not reported.